Nektar Therapeutics (NASDAQ:NKTR) CAO Jillian B. Thomsen sold 2,545 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $82.94, for a total value of $211,082.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at $83.45 on Wednesday. Nektar Therapeutics has a one year low of $12.50 and a one year high of $99.02. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91. The company has a market capitalization of $13,381.02, a PE ratio of -115.90 and a beta of 2.04.
Several institutional investors and hedge funds have recently modified their holdings of NKTR. BB&T Investment Services Inc. purchased a new stake in shares of Nektar Therapeutics in the fourth quarter worth about $119,000. Meeder Asset Management Inc. purchased a new stake in shares of Nektar Therapeutics in the fourth quarter worth about $121,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Nektar Therapeutics in the third quarter worth about $129,000. Mark Sheptoff Financial Planning LLC boosted its stake in shares of Nektar Therapeutics by 79.4% in the third quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,700 shares during the last quarter. Finally, SeaCrest Wealth Management LLC purchased a new stake in shares of Nektar Therapeutics in the fourth quarter worth about $200,000. Hedge funds and other institutional investors own 96.23% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NKTR) CAO Jillian B. Thomsen Sells 2,545 Shares” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/02/21/nektar-therapeutics-nktr-cao-jillian-b-thomsen-sells-2545-shares.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.